Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast

Cancer Immunity

Volumn 10, Issue , 2010, Pages

  Lim, Kok Haw Jonathan ^a   Telisinghe, Premasiri Upali ^b   Abdullah, Muhd Syafiq ^b   Ramasamy, Ranjan ^a  

^a UNIVERSITI BRUNEI DARUSSALAM   (Brunei Darussalam)

^b RIPAS HOSPITAL   (Brunei Darussalam)

Author keywords

Atypical medullary carcinoma; Breast; Human; Immunohistochemistry; Medullary carcinoma; TILs

Indexed keywords

BIOLOGICAL MARKER; CD20 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BREAST CARCINOMA; BRUNEI DARUSSALAM; CANCER RELAPSE; CANCER SURVIVAL; CELL LINEAGE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLARY CARCINOMA; METASTASIS; ONCOGENE NEU; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 76149131356     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with a 10-year follow up. Cancer 1977; 40: 1365-1385. (PMID: 907958)
2. Sternberg SS, Antonioli DA, Carter D, Mills SE, Oberman HA. (Eds.) Diagnostic Surgical Pathology 3rd edition. Philadelphia (PA): Lippincott Williams & Wilkins; 1999.
3. Jensen ML, Kiaer H, Andersen J, Jensen V, Melsen F. Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology 1997; 30: 523-532. (PMID: 9205856)
4. Pedersen L, Zedeler K, Holck S, Schiødt T, Mouridsen HT. Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer 1995; 31: 2289-2295. (PMID: 8652258)
5. Wargotz ES, Silverberg SG. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Human Pathol 1988; 19: 1340-1346. (PMID: 2846422)
6. Rapin V, Contesso G, Mouriesse H, Bertin F, Lacombe MJ, Piekarski JD, Travagli JP, Gadenne C, Friedman S. Medullary breast carcinoma. A re-evaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988; 61: 2503-2510. (PMID: 2835145)
7. Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 2005; 446: 10-14. (PMID: 15660281)
8. Tamiolakis D, Simopoulos C, Cheva A, Lambropoulou M, Kotini A, Jivannakis T, Papadopoulos N. Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Eur J Gynaecol Oncol 2002; 23: 433-436. (PMID: 12440819)
9. Yakirevich E, Izhak OB, Rennert G, Kovacs ZG, Resnick MB. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol 1999; 12: 1050-1056. (PMID: 10574602)
10. Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, Glassy MC. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol 2005; 175: 2278-2285. (PMID: 16081796)
11. Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res 2001; 61: 7889-7899. (PMID: 11691809)
12. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Rev Immunol 2006; 6: 715-727. (PMID: 16977338)
13. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nature Rev Immunol 2006; 6: 836-848. (PMID: 17063185)
14. Hansen MH, Nielsen H, Ditzel HJ. The tumour-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 2001; 98: 12659-12664. (PMID: 11606714)
15. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer. Prognostic factor, predictive factor and target for therapy. Oncologist 1998; 3: 237-252. (PMID: 10388110)
16. Jones C, Lakhani SR. Prognostic and predictive factors in breast cancer. Brunei Int Med J 2000; 2: 147-169.
17. Kang FR, Telisinghe PU, bin Abdallah S, Ramasamy R. Breast cancer in Brunei Darussalam - Differential community distribution and an analysis of common molecular tumour markers. Brunei Darussalam J Health 2007; 2: 23-30.
18. Orlando L, Renner G, Rocca A, Curigliano G, Colleoni M, Severi G, Peruzzotti G, Cinieri S, Viale G, Sanna G, Goldhirsch A. Are highgrade breast cancers with no steroid hormone expression alike? The special case of the medullary phenotype. Ann Oncol 2005; 16: 1094-1099. (PMID: 15855225)
19. Old LJ. Cancer vaccines: an overview. Cancer Immun 2008; 8 Suppl 1: 1. URL: http://www.cancerimmunity.org/v8suppl1p1/ 080104.htm